Evaluation of cardio-protective effects of a Novel SGLT2 inhibitor beyond glycemic control in preclinical models
The heart-protective effects of a novel SGLT2 inhibitor (NSI) in diabetic cardiomyopathy, beyond blood sugar control is of interest. NSI was compared with dapagliflozin and <i>Terminalia Arjuna</i> (TA) using preclinical models. Data showed that NSI significantly reduced cardiac injury markers, improved cardiac function and exhibited strong antioxidant properties, outperforming dapagliflozin and matching TA in efficacy. NSI also restored left ventricular ejection fraction and reduced myocardial fibrosis. Thus, we show that NSI may be a promising multifunctional treatment for cardiovascular issues in diabetes.
Authors
- Renju Ravi (ORCID: https://orcid.org/0000-0002-9318-363X)
- Amrit Podder (ORCID: https://orcid.org/0000-0002-9816-3347)
- Sunil Kumar (ORCID: https://orcid.org/0000-0001-9905-4831)
- Sangeeta Gupta
- Ved Prakash
- Renuka Kattimani
Institutions
- Baba Raghav Das Medical College (IN)
- Birla Institute of Technology and Science - Hyderabad Campus (IN)
- Teerthanker Mahaveer Medical College & Research Centre (IN)
- ESIC Hospital (IN)
- Institute of Medical Sciences (IN)
- All India Institute of Medical Sciences (IN)
- Deen Dayal Upadhyaya Gorakhpur University (IN)
- Banaras Hindu University (IN)
- Jazan University (SA)
Publication Details
- Journal
- Bioinformation
- Published
- 2025-08-31
- DOI
- https://doi.org/10.6026/973206300212459
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.59